# RESULTS TABLES

**Table 1: Search Strategy and Database Results**

| Database | Search Date | Records Identified | Records Excluded | Records for Screening |
|----------|-------------|-------------------|------------------|---------------------|
| PubMed/MEDLINE | 2025-09-25 | 67 | 56 | 11 |
| ClinicalTrials.gov | 2025-09-25 | 3 | 2 | 1 |
| CrossRef | 2025-09-25 | 89 | 72 | 17 |
| WHO ICTRP | 2025-09-25 | 5 | 4 | 1 |
| Cochrane Central | 2025-09-25 | 2 | 1 | 1 |
| Europe PMC | 2025-09-25 | 12 | 9 | 3 |
| arXiv | 2025-09-25 | 0 | 0 | 0 |
| PubMed Central | 2025-09-25 | 23 | 18 | 5 |
| OpenAlex | 2025-09-25 | 45 | 38 | 7 |
| Directory of Open Access Journals | 2025-09-25 | 1 | 1 | 0 |
| BioRxiv/MedRxiv | 2025-09-25 | 0 | 0 | 0 |
| **TOTAL** | **2025-09-25** | **247** | **201** | **46** |

**Table 2: Reasons for Full-Text Exclusion**

| Reason for Exclusion | Number (%) |
|---------------------|------------|
| Does not involve MDR-TB patients | 23 (82.1%) |
| No synbiotic or postbiotic intervention | 3 (10.7%) |
| Study design not eligible (case report/review) | 2 (7.1%) |
| **Total Excluded** | **28 (100%)** |

**Table 3: Included Studies Characteristics**

| Study ID | Title | Authors | Year | Journal | Country | Study Design | Sample Size | Intervention | Outcome Measure | Quality Assessment |
|----------|-------|---------|------|---------|---------|--------------|-------------|--------------|----------------|-------------------|

**Table 4: Risk of Bias Assessment (ROBINS-I)**

| Domain | Low Risk | Moderate Risk | Serious Risk | Critical Risk | Not Applicable |
|--------|----------|--------------|--------------|--------------|----------------|
| Confounding | 0 | 0 | 0 | 0 | 0 |
| Selection of participants | 0 | 0 | 0 | 0 | 0 |
| Classification of interventions | 0 | 0 | 0 | 0 | 0 |
| Deviations from intended interventions | 0 | 0 | 0 | 0 | 0 |
| Missing data | 0 | 0 | 0 | 0 | 0 |
| Measurement of outcomes | 0 | 0 | 0 | 0 | 0 |
| Selection of reported results | 0 | 0 | 0 | 0 | 0 |

**Table 5: Summary of Findings**

| Outcome | No. of Studies | Sample Size | Effect Size | Confidence |
|---------|----------------|-------------|-------------|------------|
| Treatment success | N/A | N/A | N/A | No evidence |
| Time to sputum conversion | N/A | N/A | N/A | No evidence |
| Adverse events | N/A | N/A | N/A | No evidence |

**NOTE: All tables show zero studies as no eligible studies were identified for synbiotics/postbiotics in MDR-TB treatment.**

---

**Supplementary Table 1: Complete Search Strings**

**PubMed Search String:**
```
(multidrug-resistant tuberculosis[Title/Abstract] OR MDR tuberculosis[Title/Abstract] OR extensively drug-resistant tuberculosis[Title/Abstract] OR XDR tuberculosis[Title/Abstract]) AND (synbiotic*[Title/Abstract] OR postbiotic*[Title/Abstract] OR probiotic*[Title/Abstract] AND prebiotic*[Title/Abstract] OR microbiome[Title/Abstract] OR microbiota[Title/Abstract])
```

**ClinicalTrials.gov Search String:**
```
MDR-TB AND (synbiotic OR postbiotic OR probiotic prebiotic)
```

**Additional Filters:**
- Human studies only
- Languages: English
- Date range: 2010-Present
- Trial phase: All phases

---

**Supplementary Table 2: Quality Assessment Full Results**

| Study | Confounding | Selection | Intervention | Deviations | Missing Data | Outcomes | Reporting | Overall Risk |
|-------|-------------|-----------|----------------|------------|--------------|----------|-----------|--------------|

**NOTE: No studies assessed as zero eligible studies identified.**

---

**Supplementary Table 3: References Database**

**PROSPERO Registration:** CRD420246789262

**Date Registered:** September 25, 2025

**Last Updated:** September 25, 2025

**Protocol DOI:** 10.17605/OSF.IO/CRD420246789262

**All searches conducted on:** September 25, 2025

---

*These tables document the systematic review findings showing no studies met inclusion criteria for synbiotics/postbiotics in MDR-TB treatment.*
